Key opinion leaders compare and contrast the most frequently observed causes of BTK inhibitor intolerance in clinical practice among patients treated with ibrutinib, acalabrutinib, or zanubrutinib.
What is the most common cause of BTKi intolerance you observe in the practice setting among patients receiving ibrutinib? Acalabrutinib or Zanubrutinib?
At what point during treatment does intolerance typically occur?Dr davids @39:30 – dose reduce...once per day...tyr to get back up to full dose and rechallenge with acala.
When may BTKi intolerance impact continuation of therapy and how do you manage these scenarios?